Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases

Frontiers in Cell and Developmental Biology, Journal Year: 2024, Volume and Issue: 12

Published: July 16, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty (NAFLD), is the most common disorder worldwide, with an estimated global prevalence of more than 31%. steatohepatitis (MASH), formerly (NASH), a progressive form MASLD characterized by hepatic steatosis, inflammation, and fibrosis. This review aims to provide comprehensive analysis extrahepatic manifestations MASH, focusing on chronic diseases related cardiovascular, muscular, renal systems. A systematic published studies literature was conducted summarize findings systemic impacts MASH. The focused association MASH metabolic comorbidities, cardiovascular mortality, sarcopenia, kidney disease. Mechanistic insights into concept lipotoxic inflammatory "spill over" from MASH-affected were also explored. are highly associated (50%-80%) other comorbidities such impaired insulin response, type 2 diabetes, dyslipidemia, hypertriglyceridemia, hypertension. Furthermore, 90% obese patients diabetes have Data suggest that in middle-aged individuals (especially those aged 45-54), independent risk factor for plays crucial role mediating pathological effects observed. Understanding multifaceted impact heart, muscle, early detection stratification. knowledge timely implementing management strategies addressing multi-organ involvement pathogenesis.

Language: Английский

---

Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(4), P. 1778 - 1778

Published: Feb. 19, 2025

In recent years, “metabolic dysfunction-associated steatotic liver disease” (MASLD) has been proposed to better connect disease metabolic dysfunction, which is the most common chronic worldwide. MASLD affects more than 30% of individuals globally, and it diagnosed by combination hepatic steatosis obesity, type 2 diabetes, or two risk factors. begins with buildup extra fat, often greater 5%, within liver, causing hepatocytes become stressed. This can proceed a severe form, steatohepatitis (MASH), in 20–30% people, where inflammation causes tissue fibrosis, limits blood flow over time. As fibrosis worsens, MASH may lead cirrhosis, failure, even cancer. While pathophysiology not fully known, current “multiple-hits” concept proposes that dietary lifestyle factors, genetic epigenetic factors contribute elevated oxidative stress inflammation, fibrosis. review article provides an overview pathogenesis evaluates existing therapies as well pharmacological drugs are currently being studied clinical trials for MASH.

Language: Английский

---

Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(4), P. 1589 - 1589

Published: Feb. 13, 2025

Non-alcoholic fatty liver disease (NAFLD), now referred to as metabolic dysfunction-associated steatotic (MASLD), is the most prevalent disorder globally, linked obesity, type 2 diabetes, and cardiovascular risk. Understanding its potential progression from simple steatosis cirrhosis hepatocellular carcinoma (HCC) crucial for patient management treatment strategies. The disease's complexity requires innovative approaches early detection personalized care. Omics technologies-such genomics, transcriptomics, proteomics, metabolomics, exposomics-are revolutionizing study of MASLD. These high-throughput techniques allow a deeper exploration molecular mechanisms driving progression. Genomics can identify genetic predispositions, whilst transcriptomics proteomics reveal changes in gene expression protein profiles during evolution. Metabolomics offers insights into alterations associated with MASLD, while exposomics links environmental exposures MASLD pathology. By integrating data various omics platforms, researchers map out intricate biochemical pathways involved This review discusses roles technologies enhancing understanding highlights diagnostic therapeutic targets within spectrum, emphasizing need non-invasive tools staging development.

Language: Английский

---

Quantitative imaging of species-specific lipid transport in mammalian cells

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: May 17, 2024

Abstract Eukaryotic cells produce over 1000 different lipid species which tune organelle membrane properties, control signalling and store energy 1,2 . How are selectively sorted between organelles to maintain specific identities is largely unknown due the difficulty image transport in 3 Here, we measured metabolism of individual mammalian using time-resolved fluorescence imaging bifunctional probes combination with ultra-high resolution mass spectrometry mathematical modelling. Quantification flux revealed that directional, non-vesicular responsible for fast, species-selective sorting compared slow, unspecific vesicular trafficking. Using genetic perturbations, found coupling active flipping passive a mechanism directional transport. Comparison metabolic conversion rates showed dominates distribution lipids while species-specific phospholipid controls neutral accumulation. Our results provide first quantitative map retrograde 4 We anticipate our pipeline mapping through physical chemical space will boost understanding cell biology disease.

Language: Английский

---

From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome – current insights and future directions

Clinical Diabetes and Endocrinology, Journal Year: 2024, Volume and Issue: 10(1)

Published: Dec. 2, 2024

Language: Английский

---

Links between fecal microplastics and parameters related to metabolic dysfunction-associated steatotic liver disease (MASLD) in humans: An exploratory study

The Science of The Total Environment, Journal Year: 2024, Volume and Issue: 953, P. 176153 - 176153

Published: Sept. 10, 2024

Language: Английский

---

Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy

Frontiers in Cell and Developmental Biology, Journal Year: 2024, Volume and Issue: 12

Published: Sept. 11, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a worldwide health epidemic with global occurrence of approximately 30%. The pathogenesis MASLD complex, multisystem disorder driven by multiple factors, including genetics, lifestyle, and the environment. Patient heterogeneity presents challenges in developing therapeutics, creating patient cohorts for clinical trials, optimizing therapeutic strategies specific cohorts. Implementing pre-clinical experimental models drug development creates significant challenge as simple

Language: Английский

---

Genetic variants associated with metabolic dysfunction-associated fatty liver diseases in a Korean population

European journal of medical research, Journal Year: 2025, Volume and Issue: 30(1)

Published: April 22, 2025

Language: Английский

---

Mechanistic study of a triterpenoid-enriched fraction derived from Cynomorium songaricum against NAFLD: An integrative elucidation

Phytomedicine, Journal Year: 2025, Volume and Issue: unknown, P. 156782 - 156782

Published: April 1, 2025

Language: Английский

---

Effects of Lifestyle Interventions on Metabolic Dysfunction-Associated Steatotic Liver Disease

Lifestyle Medicine, Journal Year: 2025, Volume and Issue: unknown, P. 199 - 215

Published: Jan. 1, 2025

Language: Английский

---